Abstract
From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here
| Original language | English |
|---|---|
| Title of host publication | Phosphoinositide 3-kinase in Health and Disease |
| Editors | Christian Rommel, Bart Vanhaesebroeck, Peter K Vogt |
| Place of Publication | US |
| Publisher | Springer |
| Pages | 203 - 224 |
| Number of pages | 22 |
| Edition | 1st |
| ISBN (Print) | 9783642136627 |
| Publication status | Published - 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver